Korsana Biosciences develops THETA-enabled antibody therapies for neurodegenerative diseases including Alzheimer’s.
Korsana Biosciences has raised $150.0M in total funding. The most recent round was Series A. The last funding was announced in September 2025.
Korsana Biosciences's investors include Janus Henderson Investors, TCG Crossover, Wellington Management, Foresite Capital, Sanofi Ventures.
Korsana Biosciences is headquartered in Waltham, United States.
Korsana Biosciences develops THETA-enabled antibody therapies for neurodegenerative diseases including Alzheimer’s.
Korsana Biosciences is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Korsana Biosciences — Funding & Investors." VCBacked, September 1, 2025, https://www.vcbacked.co/company/korsana-biosciences. Accessed July 20, 2026.
VCBacked. (2025). Korsana Biosciences — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/korsana-biosciences
{{cite web |title=Korsana Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/korsana-biosciences |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated